TRITEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRITEC (TRITEC).
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
| Metabolism | Hepatic via N-demethylation and S-oxidation; minor metabolism by CYP450; excreted renally as unchanged drug and metabolites. |
| Excretion | Renal: 60% unchanged; fecal: 35% (mainly metabolites) |
| Half-life | 2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min) |
| Protein binding | 93% (bound to albumin) |
| Volume of Distribution | 1.5 L/kg (indicating extensive tissue distribution) |
| Bioavailability | Oral: 65-70% (due to first-pass metabolism); Topical: negligible systemic absorption (approximately 1.5%) |
| Onset of Action | Oral: 1 hour; Topical: 2-3 weeks for significant hair regrowth |
| Duration of Action | 8-12 hours after single dose; topical: continuous use required to maintain effect |
| Molecular Weight | 334.39 |
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (CrCl <10 mL/min), use with caution; dose reduction to 150 mg once daily may be considered. |
| Liver impairment | No specific dose adjustment recommended for hepatic impairment; use with caution in severe hepatic dysfunction. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | No specific dose adjustment required, but monitor for adverse effects due to potential age-related decline in renal function. |
| 1st trimester | Avoid; associated with fetal malformations in animal studies. Use only if clearly needed and benefit outweighs risk. |
| 2nd trimester | Avoid; limited human data but potential for fetal harm. Use only if benefit outweighs risk. |
| 3rd trimester | Avoid; risk of premature ductus closure in third trimester. Contraindicated near term. |
Clinical note
Comprehensive clinical and safety monograph for TRITEC (TRITEC).
| Placental transfer | Crosses placenta in animals; unknown in humans. Molecular weight <500 Da suggests potential for transfer. |
| Breastfeeding | No data on excretion in human milk. Due to potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother. |
■ FDA Black Box Warning
Not available
| Serious Effects |
Hypersensitivity to ribavirin or any componentPregnancyHemoglobinopathies (e.g., thalassemia major, sickle cell anemia)Severe renal impairment (CrCl <30 mL/min)Severe hepatic impairment or decompensated cirrhosisAutoimmune hepatitisConcurrent use of didanosine
| Precautions | May cause confusion, delirium, hallucinations, especially in elderly or renally impaired patients, Risk of acute porphyria; avoid in patients with porphyria, May mask symptoms of gastric malignancy, Adjust dose in renal impairment (CrCl <50 mL/min), Potential for neuropsychiatric events (reversible with discontinuation), Hypersensitivity reactions (rare) |
| Food/Dietary | Avoid high-fat meals as they delay absorption. No known specific food interactions. |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated) based on limited data and theoretical risk of infant harm. |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; insufficient human data. Avoid first trimester use unless clearly needed. |
| Fetal Monitoring | Monitor maternal renal function and electrolytes; fetal ultrasound if used during pregnancy. |
| Fertility Effects | No known effect on fertility in animal studies; limited human data. |
| Clinical Pearls | Tritec (ranitidine) is contraindicated in patients with acute porphyria. Monitoring of liver function tests is recommended in hepatic impairment. Dosage adjustment required in renal impairment (CrCl <50 mL/min). Avoid use with antacids within 1 hour of administration. |
| Patient Advice | Take exactly as prescribed; do not exceed recommended dose. · Swallow tablet whole with water; do not crush or chew. · Avoid alcohol and NSAIDs to reduce gastric irritation. · Report any unusual bleeding, bruising, or persistent abdominal pain. · Inform healthcare provider if you are pregnant or breastfeeding. |